CD274 and neoplasm: This dual activity suggests that Roscovitine may have therapeutic potential in combination with standard antibody-based ICB in NSCLC, allowing more effective antibody-mediated blockade of PD-L1 by both reducing PD-L1 expression and modulating the inflammatory tumor microenvironment.